Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Acquisition of CyDex) (Details)

v3.7.0.1
Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - Contingent Consideration Classified as Equity
3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Credit Derivatives [Line Items]    
Revenue volatility 25.00% 25.00%
Average probability of commercialization 12.50% 12.50%
Market price of risk 0.03 0.03
Credit rating BB BB
Equity risk premium 6.00% 6.00%